Edition:
United States

Fresenius Medical Care AG & Co KGaA (FMEG.DE)

FMEG.DE on Xetra

80.53EUR
8:30am EDT
Change (% chg)

€-0.51 (-0.63%)
Prev Close
€81.04
Open
€80.52
Day's High
€80.69
Day's Low
€80.13
Volume
203,955
Avg. Vol
569,953
52-wk High
€89.22
52-wk Low
€70.69

FMEG.DE

Chart for FMEG.DE

About

Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company's segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the... (more)

Overall

Beta: 0.34
Market Cap(Mil.): €24,949.06
Shares Outstanding(Mil.): 307.86
Dividend: 0.96
Yield (%): 1.18

Financials

  FMEG.DE Industry Sector
P/E (TTM): 20.06 29.89 16.47
EPS (TTM): 4.04 -- --
ROI: 7.99 7.14 -8.42
ROE: 12.36 11.44 -8.02

Fresenius Medical launches cost savings programme

FRANKFURT, June 8 German kidney dialysis specialist Fresenius Medical Care on Thursday said it was targeting up to 200 million euros ($225 million) in annual cost savings from 2020 as part of a new efficiency drive.

Jun 08 2017

Fitch Rates Fresenius Medical Care Bonds 'BBB-'

(The following statement was released by the rating agency) LONDON, May 25 (Fitch) Fitch Ratings has assigned senior unsecured ratings of 'BBB-' to debt instruments issued by the various finance companies of Fresenius Medical Care AG & Co. KG (FMC). The issuing companies are FMC Finance VII S,A., FMC Finance VIII S.A., Fresenius Medical Care US Finance II, Inc. and Fresenius Medical Care US Finance, Inc. The senior unsecured ratings are in line with FMC's Long-Term Issuer Default Rating (IDR) of

May 25 2017

Swiss stocks - Factors to watch on May 16

ZURICH, May 16 The Swiss blue-chip SMI was seen opening 0.1 percent lower at 9,099 points on Tuesday, according to premarket indications by bank Julius Baer .

May 16 2017

BRIEF-Vifor Pharma and Akebia announce license agreement to provide Vadadustat to Fresenius in U.S.

* Vifor Pharma and Akebia announce exclusive license agreement to provide Vadadustat to Fresenius medical care in the U.S. Upon FDA approval

May 16 2017

BRIEF-Akebia and Vifor Pharma announce license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval

* Akebia and Vifor Pharma announce exclusive license agreement to provide vadadustat to Fresenius Medical Care in the U.S. upon FDA approval

May 15 2017

UPDATE 1-Fresenius ups guidance on growth at generic drugs unit

* Unit FMC shored up by reimbursement, drug cost control (Adds FMC results, premarket shares)

May 03 2017

Dialysis provider FMC posts higher earnings

FRANKFURT Fresenius Medical Care , the German kidney dialysis provider which derives about three quarters of sales from North America, posted a 17 percent gain in quarterly adjusted net income, benefiting from higher reimbursement rates and lower costs of medicines for dialysis patients.

May 03 2017

Dialysis provider FMC posts higher earnings

FRANKFURT, May 3 Fresenius Medical Care , the German kidney dialysis provider which derives about three quarters of sales from North America, posted a 17 percent gain in quarterly adjusted net income, benefiting from higher reimbursement rates and lower costs of medicines for dialysis patients.

May 03 2017

Fitch: Fresenius Deals Offer Growth, Diversification; No Rating Impact

(The following statement was released by the rating agency) LONDON, April 26 (Fitch) Fitch Ratings says transactions by German healthcare group Fresenius SE & Co KGaA (FSE; BBB-/Stable) - including Fresenius Medical Care AG & Co. KGaA (FMC; together, Fresenius) - that enable its diversification into US generics through Akorn and biosimilars through Merck, will enhance its business risk profile. The group is well anchored in investment-grade territory, although the transactions will exhaust any f

Apr 26 2017

UPDATE 1-Fresenius aims for double-digit growth through 2020

* FMC sees slowing profit growth in 2017 (Adds details, Fresenius results)

Feb 22 2017

Earnings vs. Estimates